This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Bisichem Co., Ltd.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: The Innovations of Namhee Kim
Introduction
Namhee Kim is a prominent inventor based in Seongnam-si, South Korea. He has made significant contributions to the field of pharmaceuticals through his innovative research and development of novel compounds. His work focuses on creating solutions for various medical conditions, showcasing his dedication to improving healthcare.
Latest Patents
Namhee Kim holds a patent for "Fused ring heteroaryl compounds and use thereof." This invention provides novel substituted heterocyclic compounds represented by Formula I, or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer, or prodrug thereof. The compounds can be utilized as inhibitors of ALK5 and are beneficial in treating chronic fibrosis, vascular disorders, obesity, diabetes, autoimmune diseases, and cancer. He has 1 patent to his name, reflecting his innovative contributions to the pharmaceutical industry.
Career Highlights
Namhee Kim is associated with Bisichem Co., Ltd., where he continues to advance his research and development efforts. His work at the company emphasizes the importance of innovation in creating effective treatments for various health issues. His expertise and dedication have positioned him as a valuable asset in the field of pharmaceutical research.
Collaborations
Namhee Kim collaborates with talented individuals such as Jinwoo Lee and Byungnam Kang. These partnerships enhance the research and development process, allowing for a more comprehensive approach to innovation in pharmaceuticals.
Conclusion
Namhee Kim's contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his commitment to advancing medical science. His work continues to pave the way for new treatments that can significantly impact patient care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile